The global market for Protease Inhibitors was valued at US$ 4123 million in the year 2024 and is projected to reach a revised size of US$ 5639 million by 2031, growing at a CAGR of 4.6% during the forecast period.
Protease inhibitors (PIs) are medications that treat viral infections. They work by preventing a virus from making more copies of itself. They"re most commonly used as an antiretroviral to manage HIV/AIDS. They can also be used to treat hepatitis C and COVID-19.
North American market for Protease Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Protease Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Protease Inhibitors include CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (Germany), LFB S.A (France), Bio Product Laboratory Ltd. (U.K.), Sanquin (Netherlands), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Protease Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Protease Inhibitors.
The Protease Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Protease Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Protease Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
CSL Ltd. (Australia)
Grifols S.A (Spain)
Baxalta Incorporated (U.S.)
Octapharma AG (Switzerland)
Kedrion S.p.A (Italy)
China Biologic Products, Inc. (China)
Biotest AG (Germany)
LFB S.A (France)
Bio Product Laboratory Ltd. (U.K.)
Sanquin (Netherlands)
Segment by Type
Reagent Grade
Pharmaceutical
Others
Segment by Application
Biotechnology
Medicine
Microbiology
Agriculture
Pharmaceuticals
Food Additives
Cosmetics
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Protease Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Protease Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Protease Inhibitors 麻豆原创 Overview
1.1 Product Definition
1.2 Protease Inhibitors by Type
1.2.1 Global Protease Inhibitors 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Reagent Grade
1.2.3 Pharmaceutical
1.2.4 Others
1.3 Protease Inhibitors by Application
1.3.1 Global Protease Inhibitors 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Biotechnology
1.3.3 Medicine
1.3.4 Microbiology
1.3.5 Agriculture
1.3.6 Pharmaceuticals
1.3.7 Food Additives
1.3.8 Cosmetics
1.4 Global Protease Inhibitors 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Protease Inhibitors Revenue 2020-2031
1.4.2 Global Protease Inhibitors Sales 2020-2031
1.4.3 Global Protease Inhibitors 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Protease Inhibitors 麻豆原创 Competition by Manufacturers
2.1 Global Protease Inhibitors Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Protease Inhibitors Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Protease Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Protease Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Protease Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Protease Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Protease Inhibitors, Date of Enter into This Industry
2.8 Global Protease Inhibitors 麻豆原创 Competitive Situation and Trends
2.8.1 Global Protease Inhibitors 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Protease Inhibitors Players 麻豆原创 Share by Revenue
2.8.3 Global Protease Inhibitors 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Protease Inhibitors 麻豆原创 Scenario by Region
3.1 Global Protease Inhibitors 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Protease Inhibitors Sales by Region: 2020-2031
3.2.1 Global Protease Inhibitors Sales by Region: 2020-2025
3.2.2 Global Protease Inhibitors Sales by Region: 2026-2031
3.3 Global Protease Inhibitors Revenue by Region: 2020-2031
3.3.1 Global Protease Inhibitors Revenue by Region: 2020-2025
3.3.2 Global Protease Inhibitors Revenue by Region: 2026-2031
3.4 North America Protease Inhibitors 麻豆原创 Facts & Figures by Country
3.4.1 North America Protease Inhibitors 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Protease Inhibitors Sales by Country (2020-2031)
3.4.3 North America Protease Inhibitors Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Protease Inhibitors 麻豆原创 Facts & Figures by Country
3.5.1 Europe Protease Inhibitors 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Protease Inhibitors Sales by Country (2020-2031)
3.5.3 Europe Protease Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Protease Inhibitors 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Protease Inhibitors 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Protease Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific Protease Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Protease Inhibitors 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Protease Inhibitors 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Protease Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America Protease Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Protease Inhibitors 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Protease Inhibitors 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Protease Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa Protease Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Protease Inhibitors Sales by Type (2020-2031)
4.1.1 Global Protease Inhibitors Sales by Type (2020-2025)
4.1.2 Global Protease Inhibitors Sales by Type (2026-2031)
4.1.3 Global Protease Inhibitors Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Protease Inhibitors Revenue by Type (2020-2031)
4.2.1 Global Protease Inhibitors Revenue by Type (2020-2025)
4.2.2 Global Protease Inhibitors Revenue by Type (2026-2031)
4.2.3 Global Protease Inhibitors Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Protease Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global Protease Inhibitors Sales by Application (2020-2031)
5.1.1 Global Protease Inhibitors Sales by Application (2020-2025)
5.1.2 Global Protease Inhibitors Sales by Application (2026-2031)
5.1.3 Global Protease Inhibitors Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Protease Inhibitors Revenue by Application (2020-2031)
5.2.1 Global Protease Inhibitors Revenue by Application (2020-2025)
5.2.2 Global Protease Inhibitors Revenue by Application (2026-2031)
5.2.3 Global Protease Inhibitors Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Protease Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 CSL Ltd. (Australia)
6.1.1 CSL Ltd. (Australia) Company Information
6.1.2 CSL Ltd. (Australia) Description and Business Overview
6.1.3 CSL Ltd. (Australia) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 CSL Ltd. (Australia) Protease Inhibitors Product Portfolio
6.1.5 CSL Ltd. (Australia) Recent Developments/Updates
6.2 Grifols S.A (Spain)
6.2.1 Grifols S.A (Spain) Company Information
6.2.2 Grifols S.A (Spain) Description and Business Overview
6.2.3 Grifols S.A (Spain) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Grifols S.A (Spain) Protease Inhibitors Product Portfolio
6.2.5 Grifols S.A (Spain) Recent Developments/Updates
6.3 Baxalta Incorporated (U.S.)
6.3.1 Baxalta Incorporated (U.S.) Company Information
6.3.2 Baxalta Incorporated (U.S.) Description and Business Overview
6.3.3 Baxalta Incorporated (U.S.) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Baxalta Incorporated (U.S.) Protease Inhibitors Product Portfolio
6.3.5 Baxalta Incorporated (U.S.) Recent Developments/Updates
6.4 Octapharma AG (Switzerland)
6.4.1 Octapharma AG (Switzerland) Company Information
6.4.2 Octapharma AG (Switzerland) Description and Business Overview
6.4.3 Octapharma AG (Switzerland) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Octapharma AG (Switzerland) Protease Inhibitors Product Portfolio
6.4.5 Octapharma AG (Switzerland) Recent Developments/Updates
6.5 Kedrion S.p.A (Italy)
6.5.1 Kedrion S.p.A (Italy) Company Information
6.5.2 Kedrion S.p.A (Italy) Description and Business Overview
6.5.3 Kedrion S.p.A (Italy) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Kedrion S.p.A (Italy) Protease Inhibitors Product Portfolio
6.5.5 Kedrion S.p.A (Italy) Recent Developments/Updates
6.6 China Biologic Products, Inc. (China)
6.6.1 China Biologic Products, Inc. (China) Company Information
6.6.2 China Biologic Products, Inc. (China) Description and Business Overview
6.6.3 China Biologic Products, Inc. (China) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 China Biologic Products, Inc. (China) Protease Inhibitors Product Portfolio
6.6.5 China Biologic Products, Inc. (China) Recent Developments/Updates
6.7 Biotest AG (Germany)
6.7.1 Biotest AG (Germany) Company Information
6.7.2 Biotest AG (Germany) Description and Business Overview
6.7.3 Biotest AG (Germany) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Biotest AG (Germany) Protease Inhibitors Product Portfolio
6.7.5 Biotest AG (Germany) Recent Developments/Updates
6.8 LFB S.A (France)
6.8.1 LFB S.A (France) Company Information
6.8.2 LFB S.A (France) Description and Business Overview
6.8.3 LFB S.A (France) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 LFB S.A (France) Protease Inhibitors Product Portfolio
6.8.5 LFB S.A (France) Recent Developments/Updates
6.9 Bio Product Laboratory Ltd. (U.K.)
6.9.1 Bio Product Laboratory Ltd. (U.K.) Company Information
6.9.2 Bio Product Laboratory Ltd. (U.K.) Description and Business Overview
6.9.3 Bio Product Laboratory Ltd. (U.K.) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bio Product Laboratory Ltd. (U.K.) Protease Inhibitors Product Portfolio
6.9.5 Bio Product Laboratory Ltd. (U.K.) Recent Developments/Updates
6.10 Sanquin (Netherlands)
6.10.1 Sanquin (Netherlands) Company Information
6.10.2 Sanquin (Netherlands) Description and Business Overview
6.10.3 Sanquin (Netherlands) Protease Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Sanquin (Netherlands) Protease Inhibitors Product Portfolio
6.10.5 Sanquin (Netherlands) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Protease Inhibitors Industry Chain Analysis
7.2 Protease Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Protease Inhibitors Production Mode & Process Analysis
7.4 Protease Inhibitors Sales and 麻豆原创ing
7.4.1 Protease Inhibitors Sales Channels
7.4.2 Protease Inhibitors Distributors
7.5 Protease Inhibitors Customer Analysis
8 Protease Inhibitors 麻豆原创 Dynamics
8.1 Protease Inhibitors Industry Trends
8.2 Protease Inhibitors 麻豆原创 Drivers
8.3 Protease Inhibitors 麻豆原创 Challenges
8.4 Protease Inhibitors 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
CSL Ltd. (Australia)
Grifols S.A (Spain)
Baxalta Incorporated (U.S.)
Octapharma AG (Switzerland)
Kedrion S.p.A (Italy)
China Biologic Products, Inc. (China)
Biotest AG (Germany)
LFB S.A (France)
Bio Product Laboratory Ltd. (U.K.)
Sanquin (Netherlands)
听
听
*If Applicable.